Signs and Symptoms

Martin, Andrew A.; Leavey, Patrick J.

doi:10.1007/978-3-319-18099-1_1

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteosarcoma is the most common bone cancer in children, adolescents, and young adults. Utilizing current standard chemotherapy and surgery, greater than 70% of patients with newly diagnosed, localized disease can achieve long-term remission (Martin and Leavey, 2015). Unfortunately, the prognosis for patients with metastatic or relapsed disease is less favorable with overall survival rates <20% despite multimodal therapy (Kager et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although some OS are low-grade variants, the vast majority are high-grade malignancies with an elevated tendency for metastatic spread to the lungs. Survival rates for children and young adults at five years after diagnosis range from about 60 to 70%, for patients with non-metastatic disease, but only from 10 to 30% for those with metastatic disease at initial diagnosis [ 6 ]. Furthermore, even in the subset of patients with non-metastatic disease at diagnosis, about 40% of patients develop metastasis at later stages [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

et al. 2018

View full text Add to dashboard Cite

Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed by surgery and post-operative chemotherapy. In order to ameliorate survival rates of patients, new therapeutic approaches have been evaluated, mainly immunotherapy with antibody-drug conjugates or immunoconjugates. These molecules consist of a carrier (frequently an antibody) joined by a linker to a toxic moiety (drug, radionuclide, or toxin). Although several clinical trials with immunoconjugates have been conducted, mainly in hematological tumors, their potential as therapeutic agents is relatively under-explored in many types of cancer. In this review, we report the immunoconjugates directed against OS surface antigens, considering the in vitro and in vivo studies. To date, several attempts have been made in preclinical settings, reporting encouraging results and demonstrating the validity of the idea. The clinical experience with glembatumumab vedotin may provide new insights into the real efficacy of antibody-drug conjugates for OS therapy, possibly giving more information about patient selection. Moreover, new opportunities could arise from the ongoing clinical trials in OS patients with unconjugated antibodies that could represent future candidates as carrier moieties of immunoconjugates.

show abstract

Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma

Wedekind

Cripe

2020

Current Advances in the Science of Osteosarcoma

View full text Add to dashboard Cite

Signs and Symptoms

Cited by 3 publications

References 29 publications

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma

Contact Info

Product

Resources

About